Cancer Letters
Volume 222, Issue 1 , Pages 17-22 , 10 May 2005

Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats

  • György Paragh

      Affiliations

    • First Department of Medicine, University of Debrecen, P.O. Box 19, Debrecen H-4012, Hungary
    • ,
  • Gabriella Fóris

      Affiliations

    • First Department of Medicine, University of Debrecen, P.O. Box 19, Debrecen H-4012, Hungary
    • Corresponding Author InformationCorresponding author. Fax: +36 52 417 385.
    • ,
  • György Paragh Jr

      Affiliations

    • Department of Dermatology, Semmelweis University, Budapest, Hungary
    • ,
  • Ildikó Seres

      Affiliations

    • First Department of Medicine, University of Debrecen, P.O. Box 19, Debrecen H-4012, Hungary
    • ,
  • Zsolt Karányi

      Affiliations

    • First Department of Medicine, University of Debrecen, P.O. Box 19, Debrecen H-4012, Hungary
    • ,
  • Péter Fülöp

      Affiliations

    • First Department of Medicine, University of Debrecen, P.O. Box 19, Debrecen H-4012, Hungary
    • ,
  • Zoltán Balogh

      Affiliations

    • First Department of Medicine, University of Debrecen, P.O. Box 19, Debrecen H-4012, Hungary
    • ,
  • Béla Kosztáczky

      Affiliations

    • First Department of Medicine, University of Debrecen, P.O. Box 19, Debrecen H-4012, Hungary
    • ,
  • Farkas Teichmann

      Affiliations

    • First Department of Medicine, University of Debrecen, P.O. Box 19, Debrecen H-4012, Hungary
    • ,
  • Pál Kertai

      Affiliations

    • Institute of Preventive Medicine, Medical and Health Science Center, University of Debrecen, Debrecen H-4012, Hungary

Received 4 March 2004 ,Revised 18 August 2004 ,Accepted 2 September 2004.

References 

  1. Corsini A, Bernini F, Quarato P, Donetti E, Bellosta S, Fumagalli R, et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology. 1996;87:458–468
  2. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Clin. Invest. 1985;76:1748–1754
  3. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 1980;21:505–517
  4. Galton DJ. The regulation of cholesterol synthesis in human cells. Int. J. Obes. 1981;5:619–625
  5. Yuan JN, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis. 1991;87:147–157
  6. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-nethylglutaryl-coenzyme A reductase inhibitors. Cancer Res. 2001;61:4885–4891
  7. Paragh G, Kertai P, Kovács P, Paragh G, Fülöp P, Fóris G. HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats. Anticancer Res. 2003;23:3949–3954
  8. Neri G, Caputo A, Terranove T. Purification of pyruvate kinase from Yoshida ascites tumor cells. Life Sci. 1970;9:507–510
  9. Rady P, Arany I, Boján F, Kertai P. Activities of four glycolytic enzymes (HK, PFK, PK, and LDH) and isozymic pattern of LDH in mouse lung tumor induced by urethan. J. Cancer Res. Clin. Oncol. 1979;95:287–289
  10. Uzvolgyi E, Katona A, Kertai P. Tumor cell implantation with use of Gelaspon gelatin sponge disc. Cancer Lett. 1990;51:1–5
  11. Parker RA, Clark RW, Sit SY, Lanier TL, Grosso RA, Wright JJ. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J. Lipid Res. 1990;31:1271–1282
  12. Zwerschke W, Mazurek S, Massimi P, Banks P, Eigenbrodt E, Jamsen-Dürr P. Modulation of type M2 pyruvate kinase activity by human papilloma virus type 16 E7 oncoprotein. Proc. Natl Acad. Sci. USA. 1999;96:1291–1296
  13. Vitale M, Matola T, Rossi G, Laezza Ch, Frenzi G, Bifulco M. Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and Caspase-3-like protease-dependent mechanism. Endocrinology. 1999;140:698–704
  14. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology. 2000;59:245–254
  15. Davignon J, Mabile L. Mechanisms of action of statins and their pleiotropic effects. Ann. Endocrinol. 2001;(Suppl. III):3–7
  16. Moyad MA, Sonnleithner M. Prostate cancer and coronary heart disease: correlation or coincidence?. Urol. Clin. North Am. 2004;31:207–212
  17. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res. 1997;17:3153–3156
  18. Eigenbrodt E, Gebracht U, Mazurek S, Presek P, Friis RR. Carbohydrate metabolism and neoplasia: new perspectives for diagnosis and therapy. Biochemical and Molecular Aspects of Selected Cancers. vol. 2. Academic Press Inc.; 1994;pp. 311–386
  19. Mazurek S, Grimm H, Oehmke M, Weisse G, Teigelkamp S, Eigenbrodt E. Tumor M2 PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res. 2000;20:5151–5154
  20. Kress S, Stein A, Maurer P, Weber B, Reichert J, Buchmann A, et al. Expression of hypoxia-inducible genes in tumor cells. J. Cancer Res. 1998;124:315–320
  21. Jung Y, Isaacs JS, Lee S, Trepel J, Liu Z, Neckers L. Hypoxia-inducible factor induction by tumor necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor κB activation. Biochem. J. 2003;370:1011–1017

PII: S0304-3835(04)00709-8

doi: 10.1016/j.canlet.2004.09.028

Cancer Letters
Volume 222, Issue 1 , Pages 17-22 , 10 May 2005

Article Tools

* Image Usage & Resolution